About us

About us

We aim for people to live longer; in good health. We develop innovative drugs against diseases caused by “inflamm-aging”, inflammatory processes that contribute to aging and age-related diseases. For that purpose, we focus on blocking midkine, a protein that plays an important role in autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer and neurodegenerative diseases.

Lyramid is a wholly owned subsidiary of Australian listed company Cellmid ASX:CDY

cellmid.png

 

Management team

bart.jpg

Bart Wuurman, CEO

Bart Wuurman is an accomplished biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing. He has extensive experience in working with research and development based companies in pharmaceutical product development in several therapeutic areas, including cancer, fibrosis and cardiovascular diseases. Bart Wuurman has previously executed successful biotech company exits in the UK and in the Netherlands. He was responsible for pharma licensing deals worth over $700 million. Bart was CEO of De Novo pharmaceuticals (UK), AM-Pharma, Lanthio Pharma and Hercules Pharmaceuticals. In 2015 Bart became Managing Director of DDF Ventures, a life-science focused venture fund with a portfolio of start-up companies in The Netherlands.

graham.jpg

Graham Robertson, CSO

Associate Professor Robertson brings to this role many years research experience in multiple biological and pathophysiological processes incorporating both clinical studies and diverse experimental approaches. A feature of his recent research has been the application of systems biology approaches including transcriptomic, proteomic and metabolomic profiling techniques to understand complex inter-organ signaling involved in chronic inflammatory diseases and cancer. Following a PhD in molecular virology and Post-Doc training at University of Oxford, Graham was affiliated with University of Sydney and Garvan Institute, Sydney before joining Cellmid in 2015. He was appointed Chief Scientific Officer of Lyramid in June 2019 with responsibility for the company’s midkine programs.

d-burg-head-2.jpg

Dr Dominic Burg, Project Manager

Dr Dominic Burg is an experienced scientist with a background in large multi-national projects in translational medicine. Dominic undertook his PhD studies at the University of NSW School of Biotechnology and Biomolecular Sciences. Following his PhD studies, Dominic underwent post-doctoral training at the University of Sydney, studying the systems biology of complex inflammatory processes underpinning cancer cachexia syndrome and proteomic profiling to discover biomarkers for colorectal cancer.

sharon-hall.jpg

Sharron Hall, Laboratory Manager

Sharron Hall is based at the Hunter Medical Research Institute in Newcastle, Australia, where she coordinates clinical studies into midkine as a biomarker. Originally trained in Pathology, Sharron has developed a wide professional network, spanning the clinical and academic sectors at the John Hunter Hospital, Newcastle, and the University of Newcastle. She co-ordinates all aspects of multidisciplinary human research, including ethics, safety, engagement with clinical practitioners, sample collection from community volunteers and laboratory processing of specimens. The use of ELISA systems for analysis has been a long-standing focus of her scientific practice and Sharron supports LYRAMID’s midkine studies in patients.

Board of Directors

maria.jpg

Ms Maria Halasz, Non-executive Chairman

Maria Halasz has been involved in the biotechnology sector for over 26 years. She spent several years as director of corporate finance managing the healthcare and biotechnology practices at investment banks. Maria is the Chief Executive Officer and Managing Director of Cellmid and has led the  acquisition of the midkine intellectual property portfolio in 2009. An accomplished public company CEO with international experience Maria has executed transactions in the US, China, Europe, Japan and the UK. Maria is a graduate of the University of Western Australia (B.Sc., MBA) and the Australian Institute of Company Directors (GAICD). She has board experience in public and private companies and has acted on advisory boards of non-profit organisations.

 
walton.jpg

Dr Fintan Walton, Non-executive director

Dr Fintan Walton is Founder and CEO of PharmaVentures Ltd, a UK based corporate advisory firm, assisting pharmaceutical and biotechnology companies worldwide in all aspects of corporate transactions, business brokering, mergers and acquisitions and licensing deals. He has transactional experience representing corporates as well as major banks, investment and merchant banks, private equity and venture capital groups. Educated at Trinity College (Dublin, Ireland), where he obtained his PhD in genetics, Dr Walton has subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992) prior to founding PharmaVentures.